Show simple item record

dc.contributor.authorMashat, M.*
dc.contributor.authorClark, Brian J.*
dc.contributor.authorAssi, Khaled H.*
dc.contributor.authorChrystyn, Henry*
dc.date.accessioned2016-11-28T14:43:13Z
dc.date.available2016-11-28T14:43:13Z
dc.date.issued2015-12-31
dc.identifier.citationMashat M, Clark BJ, Assi KH et al (2015) In vitro Performance Assessment of Recent Nebuliser Delivery Systems for Nebulisation of Approved Aerosolised Tobramycin (TOBI)®. Journal of Applied Biopharmaceutics and Pharmacokinetics. 3: 34-46.en_US
dc.identifier.urihttp://hdl.handle.net/10454/10707
dc.descriptionYesen_US
dc.description.abstractTOBI® is a recently marketed preservative and sulphate free tobramycin formulation approved by FDA for maintenance therapy for patient with cystic fibrosis. The performance of selected recent nebuliser delivery systems has been assessed using the developed method to determine the optimum combinations to deliver approved tobramycin inhaled solution (TOBI)®. A simple, sensitive and specific high performance liquid chromatographic method has been developed and used to quantitative determination of the aminoglycoside tobramycin following pre-column derivatisation with phenylisocyanate (PIC). The reaction time was 10 min at 80º C and the resulting derivative was stable for five days at room temperature. The quantitative performance of the assay was further improved by using another aminoglycoside (neomycin) as internal standard. The stable resulting PIC-tobramycin derivative was separated using a HPLC 5μm Columbus C18 column (150x4.60 mm i.d, Phenomenex). The mobile phase was consisted of acetonitrile-glacial acetic acid-water (450:5:545, v/v/v) and ultraviolet detection at (240 nm). The proposed method showed good validation data. The standard curve was linear (n=5) at seven different concentrations, ranging from 20 to 140μg/ml and the correlation coefficient (R2) of the regression line was 0.9995. The limit of detection (LOD) and limit of quantitation (LOQ) were 0.86μg/ml and 2.62μg/ml, respectively. The relative standard deviation (RSD %) was less than 0.6% for intra-day assay (n=5) and 2.5% for inter-day assay (n=5). A number of nebuliser performance comparison studies have been demonstrated for aerosolise TOBI® to choice the optimum combination produces high repirable inhaled mass of tobramycin. The objective of this study was to evaluate the performance of recent nebuliser delivery systems to nebulise approved tobramycin inhaled solution (TOBI)®.en_US
dc.language.isoenen_US
dc.relation.isreferencedbyhttp://www.pharmapublisher.com/jms/index.php/jabp/article/view/483/249en_US
dc.rights© 2015 Mashat et al.; Licensee Pharma Publisher. This is an Open Access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.en_US
dc.subjectTobramycin; TOBI; PIC derivatisation; HPLC; In vitro performance assessment; Nebuliser delivery systemsen_US
dc.titleIn vitro Performance Assessment of Recent Nebuliser Delivery Systems for Nebulisation of Approved Aerosolised Tobramycin (TOBI)®en_US
dc.status.refereedYesen_US
dc.date.Accepted2015-08-06
dc.date.application2015-12-31
dc.typeArticleen_US
dc.type.versionPublished versionen_US
refterms.dateFOA2018-07-26T09:52:26Z


Item file(s)

Thumbnail
Name:
mashat_et_al_2015.pdf
Size:
580.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record